Cytiva triples single-use consumables capacity in China

The US-based company has launched three new manufacturing lines in under ten months, with an additional eight new lines planned to launch in 2022

Cytiva, a global life sciences leader, has continued to expand its manufacturing capacity for bioprocessing single-use consumables in China. In collaboration with Wego Pharmaceutical, one of the largest healthcare technology suppliers in the country, the two companies are expanding an existing facility jointly launched in 2018.

These newly added manufacturing lines will triple the supply capacity of single-use consumables in the Asia-Pacific region.

The planned expansion will consist of an additional eight new manufacturing lines, two of which are expected to launch by the end of 2021; with the other six lines scheduled in Q3 2022.

It also adds 1300 sqm to the manufacturing area of the ISO Class 7 cleanroom and also includes a 1200 sqm warehouse to further save lead time and increase flexibility for customers.

These expansions are part of the recently-announced $1.5bn investment by Cytiva and Pall Corporation.

Product news

In addition to the increased capacity, Cytiva also brings new products, 100L to 1,000L Xcellerex mixer bags, to the expanded facility's manufacturing portfolio.

The new products will incorporate Fortem technology - Cytiva's materially advanced, single-use characterised film, and its local manufacture enhances our ability to provide business continuity for our customers.

Francis Van Parys, VP of Asia-Pacific at Cytiva, said: "With the increases in global demand, customers require more flexibility and adaptability, resulting in the growing trend of in-region for-region manufacturing. Our collaboration with Wego has proven successful for our customers in China, and this increased capacity will help the region improve manufacturing resilience with cost efficiencies and decreased lead times, while delivering an equivalent, high-quality product to our customers in the broader region."

According to the BioPlan Annual Biomanufacturing report, the adoption of single-use technology is expected to increase rapidly in clinical production and in manufacturing. More than 85% of current pre-commercial and clinical manufacturing lines/facilities are single-use.

Companies